The advisory board was composed of experts, including clinical scientists working in the establishment of UK AML MRD testing and those leading the standardization of BCR::ABL1 testing in CML, clinicians experienced in managing patients with AML-based on MRD testing results, measurement science (metrology) experts and reference material producers. The gene discussed is ABL1; the disease is acute myeloid leukemia.